PML and chronic myelogenous leukemia, BCR-ABL1 positive: Induction of ROS through niclosamide treatment in AML, parthenolide treatment in AML and CML, and arsenic trioxide treatment in PML (promyelocytic leukemia) target CSCs [75–77].